Oncternal Therapeutics (NASDAQ:ONCT) Stock Price Down 1.7%

Oncternal Therapeutics, Inc. (NASDAQ:ONCTGet Rating) shares dropped 1.7% during mid-day trading on Tuesday . The stock traded as low as $1.14 and last traded at $1.16. Approximately 94,963 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 297,784 shares. The stock had previously closed at $1.18.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Oncternal Therapeutics in a research note on Thursday, December 22nd. They issued an “overweight” rating and a $4.00 target price for the company. StockNews.com assumed coverage on Oncternal Therapeutics in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $5.33.

Oncternal Therapeutics Trading Down 1.7 %

The company has a 50 day moving average price of $1.03 and a 200 day moving average price of $1.05. The company has a market capitalization of $65.35 million, a price-to-earnings ratio of -1.45 and a beta of 1.51.

Oncternal Therapeutics (NASDAQ:ONCTGet Rating) last released its earnings results on Thursday, November 3rd. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. Oncternal Therapeutics had a negative return on equity of 52.56% and a negative net margin of 2,178.29%. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.43 million. Equities analysts predict that Oncternal Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Oncternal Therapeutics

A number of institutional investors have recently made changes to their positions in ONCT. Prudential Financial Inc. acquired a new stake in shares of Oncternal Therapeutics during the second quarter worth $32,000. Mirabella Financial Services LLP acquired a new stake in shares of Oncternal Therapeutics during the first quarter worth $38,000. Waypoint Capital Advisors LLC acquired a new stake in shares of Oncternal Therapeutics during the fourth quarter worth $38,000. Resources Investment Advisors LLC. grew its stake in shares of Oncternal Therapeutics by 33.7% during the second quarter. Resources Investment Advisors LLC. now owns 40,448 shares of the company’s stock worth $45,000 after purchasing an additional 10,200 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Oncternal Therapeutics during the second quarter worth $48,000. 16.66% of the stock is owned by institutional investors and hedge funds.

About Oncternal Therapeutics

(Get Rating)

Oncternal Therapeutics, Inc engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Further Reading

Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.